Gastroesophageal Reflux Disease (GERD)

>

The HCPLive gastroesophageal reflux disease page is a comprehensive resource for clinical news and insights on GERD. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for reflux disease, and more.

Latest News

Black and White FDA Logo | Credit: US Food and Drug Administration
FDA Accepts NDA for Vonoprazan (Voquenza) in Non-Erosive GERD

December 7th 2023

The NDA submission was supported by positive data from the phase 3 PHALCON-NERD-301 study and has been assigned a standard 10-month review with a PDUFA target action date of July 19, 2024.

Vonoprazan for the Treatment of Erosive Esophagitis: A Randomized Controlled Trial
Vonoprazan for the Treatment of Erosive Esophagitis: A Randomized Controlled Trial

December 6th 2023

FDA approves VOQUENZA ® to treat Erosive Esophagitis
FDA Approves Vonoprazan to treat Erosive Esophagitis

November 1st 2023

6 FDA Decisions Expected Before 2024
6 FDA Decisions Expected Before 2024

July 5th 2023

Serological Investigations Could Improve Screenings for Celiac Disease
Serological Investigations Could Improve Screenings for Celiac Disease

April 26th 2023

Video Interviews
Podcasts

More News

© 2024 MJH Life Sciences

All rights reserved.